This report explores important updates in kidney cancer research, including new treatment combinations, immunotherapy, potential biomarkers and advances in patient care.
#KidneyCancer #ESMO2026 #KidneyCancerResearch #IKCC
#KidneyCancer #ESMO2026 #KidneyCancerResearch #IKCC
November 2, 2026 at 2:07 PM
This report explores important updates in kidney cancer research, including new treatment combinations, immunotherapy, potential biomarkers and advances in patient care.
#KidneyCancer #ESMO2026 #KidneyCancerResearch #IKCC
#KidneyCancer #ESMO2026 #KidneyCancerResearch #IKCC
Appreciate very much this clear and well-written summary! Thank you to all involved.
#kidneycancer
@ikccorg.bsky.social
#ESMO26
#kidneycancer
@ikccorg.bsky.social
#ESMO26
November 2, 2026 at 2:55 PM
Appreciate very much this clear and well-written summary! Thank you to all involved.
#kidneycancer
@ikccorg.bsky.social
#ESMO26
#kidneycancer
@ikccorg.bsky.social
#ESMO26
Five countries – China, Korea, Turkey, the USA and Japan – have already reached the number of responses needed to receive a country report.
Let's keep going! Every response helps us better understand the needs and experiences of people affected by kidney cancer.
#GlobalPatientSurvey #KidneyCancer
Let's keep going! Every response helps us better understand the needs and experiences of people affected by kidney cancer.
#GlobalPatientSurvey #KidneyCancer
November 2, 2026 at 4:30 PM
Five countries – China, Korea, Turkey, the USA and Japan – have already reached the number of responses needed to receive a country report.
Let's keep going! Every response helps us better understand the needs and experiences of people affected by kidney cancer.
#GlobalPatientSurvey #KidneyCancer
Let's keep going! Every response helps us better understand the needs and experiences of people affected by kidney cancer.
#GlobalPatientSurvey #KidneyCancer
🔬 At #ESMO26, Laurence Albiges presented results on the reproducibility of PD-L1 status assessment in the pragmatic #CARE1 trial.
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
October 29, 2026 at 5:14 PM
🔬 At #ESMO26, Laurence Albiges presented results on the reproducibility of PD-L1 status assessment in the pragmatic #CARE1 trial.
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
#KidneyCancer #RCC #PDL1 #ClinicalResearch #PragmaticTrials
Calling all #KidneyCancer patients, carers, and survivors to share their experience in the International Kidney Cancer Coalition Global Patient Survey. Just 15 minutes to help improve the lives of patients in worldwide.
https://bit.ly/IKCC_Kidney_Cancer_Global_Survey
#AcceleratingCures
https://bit.ly/IKCC_Kidney_Cancer_Global_Survey
#AcceleratingCures
October 30, 2026 at 6:00 PM
Calling all #KidneyCancer patients, carers, and survivors to share their experience in the International Kidney Cancer Coalition Global Patient Survey. Just 15 minutes to help improve the lives of patients in worldwide.
https://bit.ly/IKCC_Kidney_Cancer_Global_Survey
#AcceleratingCures
https://bit.ly/IKCC_Kidney_Cancer_Global_Survey
#AcceleratingCures
By gathering perspectives from patients and carers worldwide, we can build a clearer picture of what is working, where improvements are needed and how kidney cancer care can be better for everyone.
#KidneyCancer #GlobalPatientSurvey #IKCC
#KidneyCancer #GlobalPatientSurvey #IKCC
November 3, 2026 at 11:56 AM
By gathering perspectives from patients and carers worldwide, we can build a clearer picture of what is working, where improvements are needed and how kidney cancer care can be better for everyone.
#KidneyCancer #GlobalPatientSurvey #IKCC
#KidneyCancer #GlobalPatientSurvey #IKCC
Not all clinical trials use placebos, and when they do, there are safeguards in place to protect participants. Interested in learning more? Explore potentially relevant #KidneyCancer clinical trials: https://kidneycan.org/clinical-trial-navigator/
#AcceleratingCures
#AcceleratingCures
November 3, 2026 at 7:00 PM
Not all clinical trials use placebos, and when they do, there are safeguards in place to protect participants. Interested in learning more? Explore potentially relevant #KidneyCancer clinical trials: https://kidneycan.org/clinical-trial-navigator/
#AcceleratingCures
#AcceleratingCures
No two #kidneycancer journeys are the same. Built with KidneyCAN & Eisai, Kompass can help guide you to tailored resources and support that fit where you are today. Explore for yourself at KidneyCancerKompass.com.
October 29, 2026 at 7:10 PM
No two #kidneycancer journeys are the same. Built with KidneyCAN & Eisai, Kompass can help guide you to tailored resources and support that fit where you are today. Explore for yourself at KidneyCancerKompass.com.
As part of IKCC’s mission to drive research and global knowledge exchange in kidney cancer, we are committed to creating opportunities for researchers from lower- and middle-income countries.
#AACR #KidneyCancer #CancerResearch
#AACR #KidneyCancer #CancerResearch
October 29, 2026 at 9:21 AM
As part of IKCC’s mission to drive research and global knowledge exchange in kidney cancer, we are committed to creating opportunities for researchers from lower- and middle-income countries.
#AACR #KidneyCancer #CancerResearch
#AACR #KidneyCancer #CancerResearch
Encouraging treatment for chromophobe #kidneycancer
A small study called the ChromoKey study tested a combination of lenvatinib plus pembrolizumab in 20 patients with a chromophobe kidney cancer that had spread to other parts of their body.
To read:
actionkidneycancer.org/encouraging-....
A small study called the ChromoKey study tested a combination of lenvatinib plus pembrolizumab in 20 patients with a chromophobe kidney cancer that had spread to other parts of their body.
To read:
actionkidneycancer.org/encouraging-....
November 2, 2026 at 9:59 AM
Encouraging treatment for chromophobe #kidneycancer
A small study called the ChromoKey study tested a combination of lenvatinib plus pembrolizumab in 20 patients with a chromophobe kidney cancer that had spread to other parts of their body.
To read:
actionkidneycancer.org/encouraging-....
A small study called the ChromoKey study tested a combination of lenvatinib plus pembrolizumab in 20 patients with a chromophobe kidney cancer that had spread to other parts of their body.
To read:
actionkidneycancer.org/encouraging-....
Please help us by completing the @IKCCorg Global Patient Survey. The more opinions and experiences we have from #kidneycancer patients and carers in the UK, the
more evidence we'll have to shape services to support families in the future.
To the survey:
actionkidneycancer.org/.../the-5th-...
more evidence we'll have to shape services to support families in the future.
To the survey:
actionkidneycancer.org/.../the-5th-...
November 2, 2026 at 2:33 PM
Please help us by completing the @IKCCorg Global Patient Survey. The more opinions and experiences we have from #kidneycancer patients and carers in the UK, the
more evidence we'll have to shape services to support families in the future.
To the survey:
actionkidneycancer.org/.../the-5th-...
more evidence we'll have to shape services to support families in the future.
To the survey:
actionkidneycancer.org/.../the-5th-...
⏱️ Just 15 minutes can make a difference for #KidneyCancer patients worldwide.
There may be several kidney cancer surveys available, but the IKCC Global Patient Survey 2026 is the only global survey available in 18 languages and across every continent: buff.ly/1lpfETh
There may be several kidney cancer surveys available, but the IKCC Global Patient Survey 2026 is the only global survey available in 18 languages and across every continent: buff.ly/1lpfETh
October 28, 2026 at 2:08 PM
⏱️ Just 15 minutes can make a difference for #KidneyCancer patients worldwide.
There may be several kidney cancer surveys available, but the IKCC Global Patient Survey 2026 is the only global survey available in 18 languages and across every continent: buff.ly/1lpfETh
There may be several kidney cancer surveys available, but the IKCC Global Patient Survey 2026 is the only global survey available in 18 languages and across every continent: buff.ly/1lpfETh
If you are a kidney cancer patient or carer, we want to hear from you! It takes just 15 minutes to complete and helps ensure that voices from around the world are heard.
#KidneyCancer #GlobalPatientSurvey
#KidneyCancer #GlobalPatientSurvey
October 27, 2026 at 12:00 PM
If you are a kidney cancer patient or carer, we want to hear from you! It takes just 15 minutes to complete and helps ensure that voices from around the world are heard.
#KidneyCancer #GlobalPatientSurvey
#KidneyCancer #GlobalPatientSurvey
#JunGuo with ivonescimab in favorable risk #kidneycancer — VEGF-PD1 bispecific treatment in favorable risk #kidneycancer — long PFS in this pt population, few pts but 65% ORR, less hypertension, a few more proteinuria.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
October 25, 2026 at 8:54 AM
#JunGuo with ivonescimab in favorable risk #kidneycancer — VEGF-PD1 bispecific treatment in favorable risk #kidneycancer — long PFS in this pt population, few pts but 65% ORR, less hypertension, a few more proteinuria.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
Call to #kidneycancer patients and carers, if you have not already done so, please help us and patients globally by completing the @ikccorg.bsky.social patient survey on kidney cancer.
Grab a hot drink, settle in and make a difference. actionkidneycancer.org/.../the-5th-...
#bypatientsforpatients
Grab a hot drink, settle in and make a difference. actionkidneycancer.org/.../the-5th-...
#bypatientsforpatients
October 27, 2026 at 11:58 AM
Call to #kidneycancer patients and carers, if you have not already done so, please help us and patients globally by completing the @ikccorg.bsky.social patient survey on kidney cancer.
Grab a hot drink, settle in and make a difference. actionkidneycancer.org/.../the-5th-...
#bypatientsforpatients
Grab a hot drink, settle in and make a difference. actionkidneycancer.org/.../the-5th-...
#bypatientsforpatients
We've started our Town Hall, where we're exploring genetic factors that impact risk of developing #kidneycancer, as well as the genetic ties to treatment response and diagnosis.
You can still register to get the link or watch the video:
https://kidneycan.org/genetics-kidney-cancer-family-risk/
You can still register to get the link or watch the video:
https://kidneycan.org/genetics-kidney-cancer-family-risk/
October 28, 2026 at 9:47 PM
We've started our Town Hall, where we're exploring genetic factors that impact risk of developing #kidneycancer, as well as the genetic ties to treatment response and diagnosis.
You can still register to get the link or watch the video:
https://kidneycan.org/genetics-kidney-cancer-family-risk/
You can still register to get the link or watch the video:
https://kidneycan.org/genetics-kidney-cancer-family-risk/
Promising kidney cancer results! In a 51-patient trial, alternating bevacizumab and pazopanib achieved median progression-free survival of 24.8 months and overall survival of 63.2 months.
medicalxpress.com/news/2026-10...
#KidneyCancer #CancerResearch #TCSC
medicalxpress.com/news/2026-10...
#KidneyCancer #CancerResearch #TCSC
Combining targeted therapies significantly boosted survival in kidney cancer study
Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progre...
medicalxpress.com
October 30, 2026 at 9:43 AM
Promising kidney cancer results! In a 51-patient trial, alternating bevacizumab and pazopanib achieved median progression-free survival of 24.8 months and overall survival of 63.2 months.
medicalxpress.com/news/2026-10...
#KidneyCancer #CancerResearch #TCSC
medicalxpress.com/news/2026-10...
#KidneyCancer #CancerResearch #TCSC
Uncovering novel therapeutic strategy for targeting #BranchedChainAminoAcid #Transamination to sensitize #ClearCellRenalCellCarcinoma to #Glutaminase inhibition doi.org/10.1158/0008... @AranyLab #ccRCC #KidneyCancer #TranslationalScience
Targeting Branched-Chain Amino Acid Transamination Sensitizes Clear Cell Renal Cell Carcinoma to Glutaminase Inhibition
Abstract. Metabolic reprogramming is a well-described hallmark of clear cell renal cell carcinoma (ccRCC). Gene copy number variation and altered gene expression data suggest enhanced branched-chain a...
doi.org
October 29, 2026 at 6:46 PM
Uncovering novel therapeutic strategy for targeting #BranchedChainAminoAcid #Transamination to sensitize #ClearCellRenalCellCarcinoma to #Glutaminase inhibition doi.org/10.1158/0008... @AranyLab #ccRCC #KidneyCancer #TranslationalScience
@DrChoueiri w last, very last update of #Keynote564 pembrolizumab for adjuvant #kidneycancer. Ongoing overall survival benefit — even 7+ years out.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
October 25, 2026 at 1:51 PM
@DrChoueiri w last, very last update of #Keynote564 pembrolizumab for adjuvant #kidneycancer. Ongoing overall survival benefit — even 7+ years out.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
Highlighting an outstanding (and free!) educational event later this week from @kidney-cancer.bsky.social and Fox Chase Cancer Center
—Register & info: www.kidneycancer.org/event/empowe...
With presentations by #KidneyCancer experts
@uretericbud.bsky.social @erplimackmd.bsky.social et al
#kcsm
—Register & info: www.kidneycancer.org/event/empowe...
With presentations by #KidneyCancer experts
@uretericbud.bsky.social @erplimackmd.bsky.social et al
#kcsm
October 26, 2026 at 12:39 PM
Highlighting an outstanding (and free!) educational event later this week from @kidney-cancer.bsky.social and Fox Chase Cancer Center
—Register & info: www.kidneycancer.org/event/empowe...
With presentations by #KidneyCancer experts
@uretericbud.bsky.social @erplimackmd.bsky.social et al
#kcsm
—Register & info: www.kidneycancer.org/event/empowe...
With presentations by #KidneyCancer experts
@uretericbud.bsky.social @erplimackmd.bsky.social et al
#kcsm
@DrChoueiri 1st up w #LITESPARK012 - Len/bel/pembro vs Len/quavonlimab/pembro vs Len/pembro for #kidneycancer. No diff in PFS or OS - likely from strong control cohort. Still no triplet for 1st line metastatic RCC.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
October 25, 2026 at 7:58 AM
@DrChoueiri 1st up w #LITESPARK012 - Len/bel/pembro vs Len/quavonlimab/pembro vs Len/pembro for #kidneycancer. No diff in PFS or OS - likely from strong control cohort. Still no triplet for 1st line metastatic RCC.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
@montypal w phase 1 data from XmAb819 ENPP3/CD3 bispecific in tx-refractory #kidneycancer — manageable CRS & promising responses dose dependent. ENPP3 very interesting target for RCC.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
October 25, 2026 at 8:42 AM
@montypal w phase 1 data from XmAb819 ENPP3/CD3 bispecific in tx-refractory #kidneycancer — manageable CRS & promising responses dose dependent. ENPP3 very interesting target for RCC.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
@DrIacovelli with phase 2 #PEPE trial - pembrolizumab w met directed treatment vs MDT in oligomet #kidneycancer — meets 1o PFS endpoint. Congrats on well done IIT. My practice is pembro after consolidative tx & great to see prospective supporting data.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
October 25, 2026 at 8:15 AM
@DrIacovelli with phase 2 #PEPE trial - pembrolizumab w met directed treatment vs MDT in oligomet #kidneycancer — meets 1o PFS endpoint. Congrats on well done IIT. My practice is pembro after consolidative tx & great to see prospective supporting data.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
@AlbigesL with 1st deliverable for #CARE1 trial, PD-L1 stratified IO-IO vs IO-TKI in metastatic #kidneycancer. Local PD-L1 status correlated well w central review. Much more to come from this pragmatic trial!
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
October 25, 2026 at 3:02 PM
@AlbigesL with 1st deliverable for #CARE1 trial, PD-L1 stratified IO-IO vs IO-TKI in metastatic #kidneycancer. Local PD-L1 status correlated well w central review. Much more to come from this pragmatic trial!
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
We were delighted to speak at the BAUN nurses conference last week.
An important part of our work is advocacy, our colleague Steve Pointon had the opportunity to present to the delegates, where he shared his experience of living with #kidneycancer and the importance of patient to patient advocacy.
An important part of our work is advocacy, our colleague Steve Pointon had the opportunity to present to the delegates, where he shared his experience of living with #kidneycancer and the importance of patient to patient advocacy.
October 27, 2026 at 10:39 AM
We were delighted to speak at the BAUN nurses conference last week.
An important part of our work is advocacy, our colleague Steve Pointon had the opportunity to present to the delegates, where he shared his experience of living with #kidneycancer and the importance of patient to patient advocacy.
An important part of our work is advocacy, our colleague Steve Pointon had the opportunity to present to the delegates, where he shared his experience of living with #kidneycancer and the importance of patient to patient advocacy.